Navigation Links
Neurocrine Biosciences to Present at Credit Suisse's 24th Annual Healthcare Conference
Date:11/4/2015

SAN DIEGO, Nov. 4, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and CEO of Neurocrine Biosciences, will be presenting at Credit Suisse's 24th Annual Healthcare Conference in Scottsdale, AZ.

The live presentation takes place on Wednesday, November 11 at 10:30am MT (9:30am PT/12:30pm ET).  The presentation will be webcast and may be accessed on the Company's website at http://www.neurocrine.com.  

Listeners are encouraged to visit the website approximately 5 minutes prior to the presentation to download or install any necessary software.  A replay of the presentation will be available on the website approximately one hour after the conclusion of the event and will be archived for one month.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc. discovers and develops innovative and life-changing pharmaceuticals, in diseases with high unmet medical needs, through its novel R&D platform, focused on neurological and endocrine based diseases and disorders.  The Company's two lead late-stage clinical programs are elagolix, a gonadotropin-releasing hormone antagonist for women's health that is partnered with AbbVie Inc., and NBI-98854, a vesicular monoamine transporter 2 inhibitor for the treatment of movement disorders.  Neurocrine intends to maintain certain commercial rights to its VMAT2 inhibitor for evolution into a fully-integrated pharmaceutical company. 

Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com.

 


'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2015 PR Newswire.
All rights reserved


Related medicine technology :

1. Neurocrine Biosciences Announces Conference Call and Webcast to Report Third Quarter 2015 Results
2. Neurocrine Announces Initiation of Phase II Clinical Study of VMAT2 Inhibitor NBI-98854 in Adults with Tourette Syndrome
3. Neurocrine Announces Positive Results from Phase III Kinect 3 Study of NBI-98854 in Tardive Dyskinesia
4. Neurocrine Biosciences Announces the Appointment of George J. Morrow to its Board of Directors
5. Neurocrine Biosciences to Present at the Morgan Stanley Global Healthcare Conference
6. Neurocrine Biosciences to Present at the Baird 2015 Healthcare Conference
7. Neurocrine Announces Completion of Enrollment into Kinect 3 Tardive Dyskinesia Study
8. Neurocrine Biosciences Reports Second Quarter 2015 Results
9. Neurocrine Biosciences Announces Conference Call and Webcast to Report Second Quarter 2015 Results
10. Neurocrine Biosciences Provides Update on NBI-77860 Program for Congenital Adrenal Hyperplasia
11. Neurocrine Biosciences to Host Analyst and Investor Day in New York City on May 21, 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2019)... ... 18, 2019 , ... “Impact of the Biofield Energy Healing ... has been named No. 1 International Best Seller and Hot New Release on ... and Theory, and Mind-Body Connection in the USA, Canada, United Kingdom, and Australia. ...
(Date:11/19/2019)... ... November 19, 2019 , ... HashCash Consultants is going to ... part of a genome research initiative for precision drugs. , The collaboration is expected ... that patients and contributors have more control over their genome records and the way ...
(Date:11/16/2019)... , ... November 16, 2019 , ... International Splash Awards ... Tools and Apps category. , Srijan got nominated for its efforts at the ... commendable work for Estee Lauder under tools and apps category. The event was organized ...
Breaking Medicine Technology:
(Date:11/16/2019)... ... November 15, 2019 , ... ... United States, access to cannabis via well-managed dispensaries becomes more and more important, ... Plans, industry-leading online provider of state-of-the-art, online, custom cannabis business plans is now ...
(Date:11/15/2019)... ... November 15, 2019 , ... Spectrum ... Newsday’s Top Long Island Workplaces for 2019. The recently announced rankings honor those ... process, Newsday worked in partnership with Energage to conduct surveys into organizational health ...
(Date:11/14/2019)... ... 2019 , ... EMulate Therapeutics, Inc., a clinical-stage therapeutic device ... have 5 poster presentations related to its medical devices for treating adult and ... in Phoenix, beginning on November 20 . , Two posters will ...
(Date:11/12/2019)... ... November 12, 2019 , ... ... individuals/organizations who have truly impacted those diagnosed with infertility. This year, Academy of ... Award for Achievement, presented at the Night of Hope Gala in New York ...
(Date:11/12/2019)... ... 2019 , ... Raintree Rehab, a division of Raintree Systems ... operators throughout the United States and Physitrack, an Apple Mobility Partner and world ... joint venture to develop and market clinical outcomes data solutions. , Both companies ...
Breaking Medicine News(10 mins):